Bacterial vaginosis-associated pathogenic bacteria (BVAB)

Bacterial vaginosis-associated pathogenic bacteria represent a complex polymicrobial consortium that displaces healthy, lactic acid-producing Lactobacillus species within the vaginal microbiome (StatPearls, 2023). The primary species involved include Gardnerella vaginalis, Atopobium vaginae, Prevotella species, and Mobiluncus species, which frequently organize into dense, multi-species biofilms on the vaginal epithelium (Journal of Infectious Diseases, 2018). These pathogens contribute to disease by producing virulence factors such as sialidases, which degrade protective mucosal barriers, and vaginolysin, a pore-forming toxin that damages host cells (Microbiology Spectrum, 2018). Clinically, this dysbiosis leads to an increased vaginal pH, the production of malodorous volatile amines, and a significantly heightened risk of obstetric complications and the acquisition of sexually transmitted infections (CDC, 2021). Therapeutic strategies primarily utilize broad-spectrum anaerobic antibiotics like metronidazole and clindamycin, although the persistence of the bacterial biofilm often leads to high rates of clinical recurrence (Nature Reviews Microbiology, 2017).

Other names

BV-associated bacteriaVaginal dysbiosis consortiumGardnerella-dominated biofilmPolymicrobial vaginal infection

Inhibition of bacterial DNA synthesis via nitro group reduction (nitroimidazoles); Inhibition of bacterial protein synthesis by binding to the 50S ribosomal subunit (lincosamides); Disruption of bacterial cell membranes and biofilm architecture (antiseptics/boric acid).